Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : CDC director says boosters needed to protect workers

09/24/2021 | 01:58pm EDT

WASHINGTON, Sept 24 (Reuters) - U.S. Centers for Disease Control and Prevention (CDC) Director Rochelle Walensky on Friday said she recommended booster shots for at-risk adult workers to protect essential workers and minority communities despite the agency's advisory committee voting against the measure.

The U.S. government is rolling out boosters starting with third doses of the Pfizer/BioNTech vaccine for Americans aged 65 and older, adults with underlying medical conditions and those in high-risk working and institutional settings, after health regulators cleared the move this week and Walensky signed off https://www.reuters.com/world/us/us-cdc-advisers-recommend-covid-19-vaccine-boosters-65-older-high-risk-2021-09-23 on it earlier on Friday.

"Many of our frontline workers, essential workers, and those in congregate settings, come from communities that have already been hardest hit," Walensky told reporters. "It was a decision about providing rather than withholding access."

Walensky's decision broke from a recommendation on Thursday by a group of expert outside advisors who felt that a narrower group of people should initially receive the extra shot. She is not obliged to follow the advice of the panel.

"This was a scientific close call. In that situation, it was my call to make," she said at a White House briefing.

Walensky said the CDC would update its guidance on boosters as needed and expects to evaluate in the coming weeks data on boosters for recipients of the Moderna and Johnson & Johnson COVID-19 vaccines.

White House coronavirus response coordinator Jeff Zients, who was also at the briefing said: "We are ready and we are prepared and implementation is happening as we speak. So there are people who will be getting booster shots as early as this afternoon."

(Reporting by Ahmed Aboulenein in Washington and Michael Erman in New Jersey; Additional reporting by Susan Heavey in Washington; Editing by Bill Berkrot)


ę Reuters 2021
All news about MODERNA, INC.
05:22pStocks rise on strong earnings reports
RE
04:46pMODERNA : Wall St ends up with Goldman; Dow posts biggest weekly rise since June
RE
03:42pJOHNSON & JOHNSON : COVID-19 Vaccine Booster Shot Receives FDA Advisory Panel Recommendati..
MT
03:42pMODERNA : NIH's Collins Says FDA Wants to Study Moderna Covid Shot in Kids Longer
MT
03:02pMODERNA : U.S. administers 406.6 mln doses of COVID-19 vaccines - CDC
RE
02:55pFDA panel recommends J&J COVID-19 booster for all recipients who got first shot
AQ
02:44pMODERNA : Wall St climbs after week of strong bank results; market set for weekly gains
RE
02:13pMODERNA : COVID SCIENCE-Statins may slightly lower COVID-19 death risk; using a different ..
RE
01:40pPFIZER : FDA panel endorses booster shot for J&J COVID-19 vaccine
AQ
01:35pEquities Climb Midday With Yields After Surprise Retail Sales Gain
MT
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 20 335 M - -
Net income 2021 12 514 M - -
Net cash 2021 12 947 M - -
P/E ratio 2021 10,9x
Yield 2021 -
Capitalization 134 B 134 B -
EV / Sales 2021 5,95x
EV / Sales 2022 5,22x
Nbr of Employees 1 300
Free-Float 90,3%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 16
Last Close Price 324,21 $
Average target price 299,31 $
Spread / Average Target -7,68%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.217.68%133 962
LONZA GROUP AG26.44%57 839
IQVIA HOLDINGS INC.37.76%47 294
SEAGEN INC.-2.83%30 963
CELLTRION, INC.-38.72%25 574
ALNYLAM PHARMACEUTICALS, INC.61.03%24 874